New hope for advanced prostate cancer: triple-drug combo enters human trials
NCT ID NCT06689163
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study tests a new drug (HRS-1167) combined with two standard treatments (abiraterone and prednisone) in 66 men with metastatic prostate cancer. The goal is to find the safest dose and see if the combination helps control the cancer. Participants must have confirmed prostate cancer that has spread and be in good overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital Of Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.